Jim Young
Overview
Explore the profile of Jim Young including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
780
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Young J, Wang S, Sacks-Davis R, Stewart A, Van Santen D, Van Der Valk M, et al.
J Acquir Immune Defic Syndr
. 2025 Feb;
PMID: 39972551
Background: Successful treatment of hepatitis C virus (HCV) can lead to liver fibrosis regression. It is not known who will experience fibrosis regression or how quickly it will occur. Methods:...
2.
Chalouni M, Van Santen D, Berenguer J, Jarrin I, Miro J, Klein M, et al.
AIDS
. 2025 Feb;
PMID: 39970192
Objective: People with HIV-HCV co-infection need antiretroviral treatment (ART) to suppress HIV and direct-acting antivirals (DAAs) to cure HCV. ART is typically prioritized, but delays in DAA initiation may increase...
3.
Young J, Short T, Steiner L, Dell-Kuster S
Eur J Anaesthesiol
. 2025 Jan;
42(2):184-186.
PMID: 39744751
No abstract available.
4.
Truscello E, Wang S, Young J, Sebastiani G, Walmsley S, Hull M, et al.
J Infect Dis
. 2024 Oct;
231(1):e101-e112.
PMID: 39417816
Background: Both human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections increase the risk of hepatic steatosis (HS), which in turn contribute to the severity and progression of liver...
5.
Sacks-Davis R, Van Santen D, Boyd A, Young J, Stewart A, Doyle J, et al.
Lancet HIV
. 2024 Jan;
11(2):e106-e116.
PMID: 38224708
Background: Reinfection after successful treatment with direct-acting antivirals is hypothesised to undermine efforts to eliminate hepatitis C virus (HCV) infection among people with HIV. We aimed to assess changes in...
6.
Van Santen D, Stewart A, Doyle J, Stoove M, Asselin J, Klein M, et al.
Int J Epidemiol
. 2023 Dec;
53(1).
PMID: 38066671
No abstract available.
7.
Young J, Wang S, Laniece Delaunay C, Cooper C, Cox J, Gill M, et al.
Int J Drug Policy
. 2023 Mar;
114:103981.
PMID: 36893502
Background: The World Health Organisation (WHO) has set targets for the rate of new infections as a way to measure progress towards the elimination of hepatitis C virus (HCV) as...
8.
Van Santen D, Sacks-Davis R, Stewart A, Boyd A, Young J, Van Der Valk M, et al.
EClinicalMedicine
. 2023 Jan;
56:101810.
PMID: 36618902
Background: Broad direct-acting antiviral (DAA) access may reduce hepatitis C virus (HCV) incidence through a "treatment as prevention" (TasP) effect. We assessed changes in primary HCV incidence following DAA access...
9.
Klein M, Young J, Ortiz-Paredes D, Wang S, Walmsley S, Wong A, et al.
Patient Prefer Adherence
. 2022 Dec;
16:3267-3281.
PMID: 36536672
Background: Many people living with HIV struggle to consistently adhere to antiretroviral therapy, fail to achieve long-term virologic control and remain at risk for HIV-related disease progression, development of resistance...
10.
Chan J, Young J, Cox J, Nitulescu R, Klein M
Can Liver J
. 2022 Aug;
1(4):231-239.
PMID: 35992622
Background: Infectious diseases (ID) physicians are important for hepatitis C virus (HCV) care delivery in Canada. Our study describes their current and intended patterns of practice, attitudes, and barriers to...